Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Fujian Haixi Pharmaceuticals Co Net Margin %?
Fujian Haixi Pharmaceuticals CoHKSE:02637 +3.28%23 Net Margin % is 30.40% as of Dec. 2025, which is 3% below its 10-year median of 31.44. GuruFocus rates HKSE:02637 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 959 Drug Manufacturers companies, Fujian Haixi Pharmaceuticals Co ranks better than 94.79% on this metric.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Fujian Haixi Pharmaceuticals Co Net Margin % Related Terms
Fujian Haixi Pharmaceuticals Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co Net Margin % Chart
Fujian Haixi Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Net Margin %
32.47
37.09
29.16
30.40
Fujian Haixi Pharmaceuticals Co Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
Net Margin %
32.47
37.09
29.16
30.40
HKSE:02637 vs ZTS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Fujian Haixi Pharmaceuticals Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fujian Haixi Pharmaceuticals Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fujian Haixi Pharmaceuticals Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Fujian Haixi Pharmaceuticals Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a Net Margin % of 30.40% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. This is near median its historical median of 31.44. Over the past decade, Fujian Haixi Pharmaceuticals Co's Net Margin % has ranged from 29.16 to 37.09. According to the industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #50 out of 959 companies in the Drug Manufacturers industry, placing it in the top 5.2%.
Is Fujian Haixi Pharmaceuticals Co's Net Margin % too high?
Fujian Haixi Pharmaceuticals Co's current Net Margin % of 30.40% is near median its 10-year median of 31.44. Over the past 10 years, this metric has ranged from a low of 29.16 to a high of 37.09. The Drug Manufacturers industry median Net Margin % is 5.44. Fujian Haixi Pharmaceuticals Co's value of 30.40% is 458.8% above this industry median. Based on the distribution chart, Fujian Haixi Pharmaceuticals Co ranks #50 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #50 out of 959 companies for Net Margin %. This places Fujian Haixi Pharmaceuticals Co in the top 5% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.44. Fujian Haixi Pharmaceuticals Co's value of 30.40% is 458.8% above this benchmark. Historically, Fujian Haixi Pharmaceuticals Co's own Net Margin % has ranged from 29.16 to 37.09 over the past decade. While the company's 10-year median is 31.44 vs. the industry median of 5.44, Fujian Haixi Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.44, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fujian Haixi Pharmaceuticals Co's current Net Margin % of 30.40% is 458.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fujian Haixi Pharmaceuticals Co's current Net Margin % is 30.40%, which is near median its own 10-year median of 31.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current Net Margin % of 30.40%. The current Net Margin % is 30.40%, which is near median its 10-year median of 31.44 and 458.8% above the Drug Manufacturers industry median of 5.44. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current Net Margin % is 30.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score
Get the complete analysis for HKSE:02637
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02637 has been successfully added to your 
